Cover Image
市場調查報告書

EpiCast Report:纖維肌痛的流行病學的預測 (∼2023年)

EpiCast Report: Fibromyalgia - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 331731
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:纖維肌痛的流行病學的預測 (∼2023年) EpiCast Report: Fibromyalgia - Epidemiology Forecast to 2023
出版日期: 2015年05月01日 內容資訊: 英文 42 Pages
簡介

全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本) 的纖維肌痛的診斷病例數,預計從2013年到2023年以0.51%的年成長率推移,從2013年的23,663,533件至2023年達到24,881,838件。

本報告提供全球主要7個國家纖維肌痛的診斷病例數及死亡人數的轉變的相關調查、疾病的背景、風險要素和並存症、各年齡、性別、重症度、原因病原的診斷病例數及死亡人數的預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
    • 美國
    • 歐盟5國
    • 日本
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法:纖維肌痛的患病案例
    • 預測的前提條件、手法:纖維肌痛的重病度
  • 前列腺癌的流行病學的預測
    • 診斷病例數
    • 診斷病例數:各年齡
    • 診斷病例數:性別
    • 標準診斷案例:各年齡
    • 診斷的分期
    • 診斷病例數:重症度別
  • 檢驗
    • 流行病學的預測考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER080-15

Fibromyalgia, also known as fibromyalgia syndrome and fibrositis, is a common form of nonarticular rheumatism that is associated with chronic, widespread musculoskeletal pain, generalized tender joints, fatigue, and a long list of wide-ranging symptoms, such as fatigue, sleep disturbances, irritable bowel syndrome (IBS), headaches, and depression. Fibromyalgia is a complex illness to diagnose and treat, as it is idiopathic, and its symptoms may be part of or overlap with other diseases.

For this analysis, GlobalData epidemiologists defined fibromyalgia using the International Classification of Diseases, Ninth Revision (ICD-9) code for fibromyalgia (729.1) and the International Classification of Diseases, Tenth Revision (ICD-10) code for fibromyalgia (M79.7). GlobalData epidemiologists used country-specific studies that provided the total prevalence of fibromyalgia using the 2010 American College of Rheumatology (ACR) classification criteria for this epidemiological forecast.

In 2013, there were 23,663,533 total prevalent cases of fibromyalgia in the 7MM. GlobalData epidemiologists forecast that the total prevalent cases in the 7MM will increase to 24,881,838 by 2023, at an Annual Growth Rate (AGR) of 0.51%. All markets, except for Germany and Japan, will see a small increase in the number of cases at varying AGRs. Since GlobalData epidemiologists held the prevalence constant throughout the forecast period, the differences observed in the total prevalent cases of fibromyalgia in the 7MM are driven by changes in the underlying population dynamics of each market.

In the 7MM, fibromyalgia epidemiological studies have shown that women have a higher total prevalence of fibromyalgia compared with men. When the 1990 ACR criteria were used to define fibromyalgia, a majority of patients with fibromyalgia were women due to the greater number of female body tender points. However, the 2010 ACR criteria are entirely symptom-based, do not require tender point counts, and provide a more accurate sex distribution of total prevalent cases of fibromyalgia (Wolfe et al., 2011). Additional studies are needed to clarify the etiology of the association between sex and fibromyalgia.

Scope

  • The Fibromyalgia EpiCast Report provides an overview of the risk factors, global, and historical trends of fibromyalgia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of fibromyalgia total prevalent cases segmented by age (in five-year increments for all ages), sex, and pain severity (mild, moderate, and severe) in these seven markets.
  • The fibromyalgia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global fibromyalgia market.
  • Quantify patient populations in the global fibromyalgia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for fibromyalgia therapeutics in each of the markets covered.
  • Identify the percentage of fibromyalgia total prevalent cases by severity.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of Fibromyalgia
    • 3.4.4. Forecast Assumptions and Methods - Fibromyalgia Pain Severity
  • 3.5. Epidemiological Forecast for Fibromyalgia (2013-2023)
    • 3.5.1. Total Prevalent Cases of Fibromyalgia
    • 3.5.2. Age-Specific Total Prevalent Cases of Fibromyalgia
    • 3.5.3. Sex-Specific Total Prevalent Cases of Fibromyalgia
    • 3.5.4. Age-Standardized Total Prevalence of Fibromyalgia
    • 3.5.5. Total Prevalent Cases of Fibromyalgia by Pain Severity
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Fibromyalgia
  • Table 2: Comparison of the ACR Criteria for Fibromyalgia Classification
  • Table 3: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of Fibromyalgia
  • Table 4: 7MM, Sources of Fibromyalgia Pain Severity Data Used to Forecast the Total Prevalent Cases of Fibromyalgia Segmented by Pain Severity
  • Table 5: 7MM, Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 6: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N (Row %), 2013
  • Table 7: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, N (Row %), 2013
  • Table 8: 7MM Total Prevalent Cases of Fibromyalgia, N (%), by Pain Severity, Both Sexes, Ages ≥10 Years, 2013

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Fibromyalgia Ages ≥10 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N, 2013
  • Figure 3: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of Fibromyalgia (%), Ages ≥10 Years, by Sex, 2013
  • Figure 5: 7MM Total Prevalent Cases of Fibromyalgia (N), by Pain Severity, Both Sexes, Ages ≥10 Years, 2013
Back to Top